The all-cash settlement was disclosed on November 9, 2012, one month after Pfizer agreed to pay $164 million to settle a separate lawsuit accusing it of misleading investors about clinical trial results for the arthritis drug Celebrex.

Wyeth shares lost more than $7.6 billion of market value on July 24, 2007, after the company said the U.S. Food and Drug Administration would not approve Pristiq to treat “hot flashes” in post-menopausal women until it learned more about potential heart and liver problems associated with the drug. Continue reading “Pfizer agrees to pay $67.5 million to settle a shareholder class action”